IDEXX LABORATORIES INC /DE — Director's Dealing 2019

Feb 20, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2019-02-15

Reporting Person: Studer Jacqueline (CVP, Gen. Counsel & Secretary)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-02-15	Common Stock	M	2866	$79.54	Acquired	8648	Direct
2019-02-15	Common Stock	S	2866	$207.5352	Disposed	5762	Direct
2019-02-15	Common Stock	M	100	$79.54	Acquired	5862	Direct
2019-02-15	Common Stock	S	100	$207.80	Disposed	5762	Direct
2019-02-15	Common Stock	M	4700	$67.85	Acquired	10462	Direct
2019-02-15	Common Stock	S	4700	$208.5389	Disposed	5762	Direct
2019-02-15	Common Stock	M	1	$67.85	Acquired	5763	Direct
2019-02-15	Common Stock	S	1	$208.90	Disposed	5762	Direct
2019-02-15	Common Stock	M	2219	$141.60	Acquired	7981	Direct
2019-02-15	Common Stock	S	2219	$208.9523	Disposed	5762	Direct
2019-02-15	Common Stock	M	1714	$178.26	Acquired	7476	Direct
2019-02-15	Common Stock	S	1714	$209.1794	Disposed	5762	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-02-15	Non-Qualified Stock Option (right-to-buy)	$79.54	M	2866	Disposed	2025-02-13	Common Stock (2866)	Direct
2019-02-15	Incentive Stock Option (right-to-buy)	$79.54	M	100	Disposed	2025-02-13	Common Stock (100)	Direct
2019-02-15	Non-Qualified Stock Option (right-to-buy)	$67.85	M	4700	Disposed	2026-02-13	Common Stock (4700)	Direct
2019-02-15	Incentive Stock Option (right-to-buy)	$67.85	M	1	Disposed	2026-02-13	Common Stock (1)	Direct
2019-02-15	Non-Qualified Stock Option (right-to-buy)	$141.60	M	2219	Disposed	2027-02-13	Common Stock (2219)	Direct
2019-02-15	Non-Qualified Stock Option (right-to-buy)	$178.26	M	1714	Disposed	2028-02-13	Common Stock (1714)	Direct

Footnotes

F1: Represents the weighted average sales price of the shares sold ranging from a low of $207.08 to a high of $208.76 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F2: Represents the weighted average sales price of the shares sold ranging from a low of $207.81 to a high of $208.90 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F3: Represents the weighted average sales price of the shares sold ranging from a low of $208.91 to a high of $209.09 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F4: Represents the weighted average sales price of the shares sold ranging from a low of $209.10 to a high of $209.37 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F5: Grant of option to buy 7,165 shares of IDEXX Laboratories, Inc. common stock that vests and is exercisable in five annual installments beginning on February 14, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

F6: Grant of option to buy 3,140 shares of Issuer common stock that vests and is exercisable in five annual installments beginning on February 14, 2016, without giving effect to Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

F7: Grant of option to buy shares of Issuer common stock exercisable in five annual installments beginning February 14, 2017.

F8: Grant of option to buy shares of Issuer common stock exercisable in five annual installments beginning February 14, 2018.

F9: Grant of option to buy shares of Issuer common stock exercisable in five annual installments beginning February 14, 2019.

F10: Not applicable.